

# The Synthesis of Fluorinated Busulfan and Puposulfan Analogs, Including an Unsymmetrical Bis-sulfonate

Ulla Lange<sup>a</sup> and Alexander Senning<sup>b,\*</sup>

<sup>a</sup>Kemisk Institut, Aarhus Universitet, DK-8000 Århus C, Denmark and <sup>b</sup>Institut for Anvendt Kemi, Danmarks Tekniske Universitet, Bygning 376, DK-2800 Lyngby, Denmark


## Dedicated to Professor Lennart Ebersson on the occasion of his 65th birthday

Lange, U. and Senning, A., 1998. The Synthesis of Fluorinated Busulfan and Puposulfan Analogs, Including an Unsymmetrical Bis-sulfonate. – Acta Chem. Scand. 52: 42–44. © Acta Chemica Scandinavica 1998.

1,4-Bis(fluoromethylsulfonyloxy)butane, 1,4-bis[3-(fluoromethylsulfonyloxy)propanoyl]piperazine and 1-(fluoromethylsulfonyloxy)-4-(methylsulfonyloxy)butane have been prepared as potential cytostatics of the busulfan type. The rate of hydrolysis of the first-mentioned has been measured.

The well established drug busulfan [1,4-bis(methylsulfonyloxy)butane] **1**<sup>1</sup> is a chemotherapeutic agent which has been widely used as an antineoplastic drug since its discovery in 1953.<sup>2</sup> It is the drug of choice for the treatment of myeloproliferative disorders such as chronic myeloid leukemia (CML),<sup>3,4</sup> and much effort has been devoted to the development of busulfan analogs.

The experimental drug puposulfan [1,4-bis[3-(methylsulfonyloxy)propanoyl]piperazine] **2**<sup>5</sup> is a busulfan analog.<sup>6</sup> Patients who have developed resistance against busulfan can benefit from puposulfan therapy because of the lack of cross resistance between **1** and **2**.





Modifications of **1** have been carried out, but fluoromethanesulfonic acid derivatives had to be omitted because the two key compounds fluoromethanesulfonyl

\* To whom correspondence should be addressed.

chloride and silver(I) fluoromethanesulfonate were unavailable at the time. The present work was initiated to close this gap.



## Results and discussion

The symmetrical busulfan and puposulfan analogs **5** and **9** were synthesized either by esterification of the appropriate diol with fluoromethanesulfonyl chloride in the presence of pyridine at room temperature [eqn. (1a)] or by heating of silver(I) fluoromethanesulfonate **6** with an alkylene diiodide in anhydrous acetonitrile [eqn. (1b)].



7, 5: X = (CH<sub>2</sub>)<sub>4</sub>

8, 9: X = CH<sub>2</sub>CH<sub>2</sub>CON(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NCOCH<sub>2</sub>CH<sub>2</sub>



Since **13** decomposes upon attempted vacuum distillation unchanged methanesulfonyl chloride could not be removed from crude **13** which was, however, satisfactory for use in step (3).

The rate of hydrolysis of the series of symmetrical alkylene bismethanesulfonates increases asymptotically with chain length to reach a constant value at C<sub>4</sub>. This increase in chemical reactivity roughly correlates with an increase in biological activity<sup>7</sup> although no unambiguous relationship has been found<sup>8</sup> and therefore a comparison of the rates of hydrolysis was made between 1,4-bis(fluoromethylsulfonyloxy)butane **5** and related compounds, cf. Table 1. The rate of hydrolysis of **5** is only slightly greater than that of its chloro analog.

Compound **5** has been tested at the National Cancer Institute (NCI) Anti-Cancer Screening Program, but did not show confirmed activity in the first *in vitro* tests. Neither does busulfan show confirmed activity in this test system which thus does not provide conclusive evidence of anti-CML activity. In the same screen, **9** and **14** exhibited marginal *in vitro* activities in the primary tests which did not warrant further *in vivo* study by the NCI.

## Experimental

**Spectroscopy.** <sup>1</sup>H NMR: Gemini (200 MHz); <sup>13</sup>C NMR: Gemini (50 MHz); Me<sub>4</sub>Si and D<sub>2</sub>O, respectively, as internal standards. IR: vs = very strong, s = strong, m = medium, w = weak.

**Materials.** The acetonitrile was dried according to a literature procedure.<sup>23</sup> All silver-containing reaction mixtures were kept in brown shaded glass vessels. The intermediates **3**,<sup>10</sup> **8**,<sup>6</sup> and **12**<sup>11</sup> were prepared according to literature procedures. It is possible, but not necessary, to purify **12** by passage through silica gel. All other starting materials were commercially available.

**Fluoromethanesulfonic acid 10.** This preparation was based on a general procedure for the conversion of aliphatic sulfonyl chlorides into the corresponding anhydrous acids.<sup>12</sup> However, the reaction time was reduced from 30 h to 3 h. A mixture of 13.3 g (100 mmol) **3**<sup>10</sup> and 250 ml methanol was refluxed for 3 h, cooled, and evaporated *in vacuo*; yield 11.3 g (99%) crude **10** as colorless oil which was used directly for the preparation of **6**. <sup>1</sup>H NMR (CD<sub>3</sub>CN): δ 8.82 (s, 1H), 5.11 (d, J =

46.8 Hz, 2H). <sup>13</sup>C NMR (CD<sub>3</sub>CN): δ 88.4 (d, J = 206 Hz).

**Silver(I) fluoromethanesulfonate 6.** This preparation was based on a general procedure for the conversion of sulfonic acids into their silver salts.<sup>13</sup> A mixture of 5.00 g (44.0 mmol) **10**, 40 ml methanol, and 8.70 g (30.5 mmol) silver carbonate was stirred vigorously for 40 min at room temperature. Excess silver carbonate was filtered off and extracted with hot acetonitrile. The combined organic phases were evaporated *in vacuo*, yield 7.40 g (76%) **6**, m.p. 170–172 °C. Elem. anal.: Calc. C 5.44%; H 0.91%; S 14.51%. Found: C 7.55%; H 1.48%; S 13.68%. <sup>1</sup>H NMR (D<sub>2</sub>O): δ 5.08 (d, J = 47.0 Hz, 2H). <sup>13</sup>C NMR (D<sub>2</sub>O): δ 92.2 (d, J = 202 Hz). IR (KBr): ν 1250vs, 1200vs, 1080m, 1020s, 790w cm<sup>-1</sup>.

**1,4-Bis(fluoromethylsulfonyloxy)butane 5: procedure (1a).** A general procedure for the synthesis of busulfan analogs was followed.<sup>13</sup> A mixture of 6.50 g (30 mmol) **6**, 4.60 g (15 mmol) **7**, and 30 ml anhydrous acetonitrile was stirred at room temperature for 7 h and then allowed to stand overnight. Precipitated silver iodide was filtered off and the organic phase evaporated *in vacuo*. After two recrystallizations of the residue from chloroform 0.95 g (23%) **5** was obtained, m.p. 60–62 °C. Elem. anal.: Calc. C: 25.53%; H 4.28%, S 22.72%. Found: C 24.92%; H 4.31%, S 22.69%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.93 (m, 2H), 4.44 (m, 2H), 5.22 (d, J = 46.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 25.7 (CH<sub>2</sub>), 72.7 (OCH<sub>2</sub>), 88.8 (d, J = 216 Hz, FCH<sub>2</sub>). IR (KBr): ν 3035m (CH stretch), 2960m, 1480m, 1455m (OCH<sub>2</sub> vibr.), 1430m, 1400s, 1375vs (SO<sub>2</sub> stretch, asym.), 1340vs, 1230s, 1180vs (SO<sub>2</sub> stretch, sym.), 1070vs (CF), 1035s, 950vs, 920vs, 860vs, 770m, 710m cm<sup>-1</sup>. MS (70 eV): *m/z* (*I*%) 281 (74) (M<sup>+</sup> - H), 140 (32) (C<sub>3</sub>H<sub>6</sub>FO<sub>3</sub>S<sup>+</sup>), 127 (17) (FCH<sub>2</sub>SO<sub>2</sub>O<sup>+</sup> = CH<sub>2</sub>), 57 (68) (C<sub>4</sub>H<sub>9</sub><sup>+</sup>), 41 (100) (C<sub>3</sub>H<sub>5</sub><sup>+</sup>), etc.

**1,4-Bis[3-(fluoromethylsulfonyloxy)propanoyl]piperazine 9.** A general procedure for the synthesis of piposulfan analogs was followed.<sup>14</sup> A mixture of 1.30 g (2.9 mmol) **8**, 1.10 g (5.0 mmol) **6**, and 10 ml anhydrous acetonitrile was refluxed for 1 h with stirring. The hot reaction mixture was filtered and the solid residue washed with hot acetonitrile. The organic phase was evaporated *in vacuo* and the resulting crystals washed successively with cold water, ethanol, and ether. After recrystallization from acetonitrile 0.28 g (27%) **9**, m.p. 126–128 °C, was obtained. Elem. anal.: Calc. C 34.12%; H 4.77%, N 6.63%, S 15.18%. Found: C 34.45%; H 4.78%; N 7.02%; S 14.62%. <sup>1</sup>H NMR (CD<sub>3</sub>CN): δ 2.82 (t, J = 6.0 Hz, 4H), 3.49 (m, 8H), 4.60 (t, J = 6.0 Hz, 4H), 5.44 (d, J = 46.0 Hz, 4H). <sup>13</sup>C NMR (CD<sub>3</sub>CN): δ 30.9 (CH<sub>2</sub>), 40.0 (COCH<sub>2</sub>), 43.6 (NCH<sub>2</sub>), 68.1 (OCH<sub>2</sub>), 87.1 (d, J = 211 Hz, FCH<sub>2</sub>), 166.9 (CO). IR (KBr): ν 2969w (CH stretch), 1645vs (tertiary amide CO), 1460w, 1445m (OCH<sub>2</sub> vibr.), 1380s (SO<sub>2</sub> stretch, asym.), 1345w, 1225m, 1180 (SO<sub>2</sub> stretch, sym.), 1080m (CF), 1035w,

Table 1. Rates of hydrolysis of busulfan analogs in 50% aqueous acetone (37 °C).

Compound	<i>k</i> <sub>1</sub> /10 <sup>3</sup> min <sup>-1</sup>
FCH <sub>2</sub> SO <sub>2</sub> O(CH <sub>2</sub> ) <sub>4</sub> OSO <sub>2</sub> CH <sub>2</sub> F ( <b>5</b> )	5.55
ClCH <sub>2</sub> SO <sub>2</sub> O(CH <sub>2</sub> ) <sub>4</sub> OSO <sub>2</sub> CH <sub>2</sub> Cl	5.30 <sup>b</sup>
BrCH <sub>2</sub> SO <sub>2</sub> O(CH <sub>2</sub> ) <sub>4</sub> OSO <sub>2</sub> CH <sub>2</sub> Br	4.33 <sup>b</sup>
ICH <sub>2</sub> SO <sub>2</sub> O(CH <sub>2</sub> ) <sub>4</sub> OSO <sub>2</sub> CH <sub>2</sub> I	2.16 <sup>b</sup>

980m, 950m, 930m, 910m, 830w, 740w  $\text{cm}^{-1}$ . MS (70 eV):  $m/z$  ( $I\%$ ) 139 (21) ( $\text{C}_6\text{H}_9\text{O}_2^+$ ), 123 (16) ( $\text{CH}_3\text{SO}_2\text{CH}_2\text{CH}_2^+$ ), 85 (100) ( $\text{C}_4\text{H}_9\text{N}_2^+$ ), 55 (74) ( $\text{C}_3\text{H}_4\text{O}^+$ ), 41 (39) ( $\text{C}_2\text{HO}^+$ ), 33 (22) ( $\text{FCH}_2^+$ ), etc.

**4-Iodobutyl methanesulfonate 13.** This procedure was based on a published synthesis of 4-chlorobutyl methanesulfonate.<sup>15</sup> Compound **12**, 2.00 g (10 mmol), was dissolved in a mixture of 5 ml dichloromethane and 1.30 g (11 mmol) **11**. The solution was cooled in an acetone-dry ice bath and 1.10 g (11 mmol) triethylamine in 3 ml dichloromethane was added. When the addition of triethylamine was complete the reaction mixture was allowed to warm to room temperature and poured into 5 ml water. The organic phase was separated, dried over anhydrous  $\text{MgSO}_4$ , and evaporated *in vacuo*; yield 1.53 g (55%) crude **13** with methanesulfonyl chloride as the main impurity. The crude product decomposed upon attempted distillation *in vacuo*.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.92 (m, 4H), 3.03 (s, 3H), 3.23 (t,  $J=6.5$  Hz, 2H), 4.27 (t,  $J=6.4$  Hz, 3H).  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{CN}$ ):  $\delta$  29.7, 30.5, 34.3, 38.0, 69.3.

**1-(Fluoromethylsulfonyloxy)-4-(methylsulfonyloxy)butane 14.** A mixture of 2.00 g (9.0 mmol) **6**, 2.50 g (9.0 mmol) **13**, and 10 ml anhydrous acetonitrile was stirred at room temperature for 1 day. Silver iodide was filtered off and the organic phase evaporated *in vacuo*. Recrystallization from ether-acetone (10:1) yielded 0.24 g (10%) **14**, m.p. 82–85°C. Elem. Anal.: Calc. C 27.27%; H 4.96%; S 24.26%. Found: C 27.42%; H 5.16%; S 24.26%.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.94 (m, 4H), 3.03 (s, 3H), 4.29 (m, 2H), 4.47 (m, 2H), 5.24 (d,  $J=46.6$  Hz, 2H).  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{CN}$ ):  $\delta$  25.7 ( $\text{CH}_2$ ), 26.1 ( $\text{CH}_2$ ), 37.9 ( $\text{CH}_3$ ), 69.3 ( $\text{OCH}_2$ ), 73.0 ( $\text{OCH}_2$ ), 88.9 (d,  $J=216$  Hz,  $\text{FCH}_2$ ). IR (KBr):  $\nu$  3020m (CH stretch), 2920m, 1470m ( $\text{OCH}_2$  vibr.), 1445m, 1415m, 1350vs ( $\text{SO}_2$  stretch, asymm.), 1240m, 1170vs ( $\text{SO}_2$  stretch, symm.), 1080m (CF), 1030m, 980s, 930vs, 855s, 765m, 720w  $\text{cm}^{-1}$ . MS (70 eV):

$m/z$  ( $I\%$ ) 264 (5) ( $M^+$ ), 169 (69) [ $\text{FCH}_2\text{SO}_3(\text{CH}_2)_4^+$ ], 151 (39) ( $\text{CH}_3\text{SO}_2\text{O}^+=\text{CH}_2$ ), 79 (53) ( $\text{CH}_3\text{SO}_2^+$ ), 71 (62) ( $\text{C}_4\text{H}_7\text{O}^+$ ), 51 (100) ( $\text{C}_4\text{H}_3^+$ ), 33 (30) ( $\text{FCH}_2^+$ ), etc.

**Rates of hydrolysis.** An acidimetric titration was carried out where the first-order rate constant  $k_1$  for the hydrolysis was calculated in the same way as for the chloro, bromo, and iodo analogs of busulfan.<sup>8</sup> The hydrolyses were carried out in 50% aqueous acetone at 37°C. The results are shown in Table I.

**Acknowledgements.** We are pleased to acknowledge financial support from *Direktor Ib Henriksens Fond* and from *Lundbeckfonden*.

## References

1. *The Merck Index*, 12th ed., 1996, No. 1529.
2. Haddow, A. and Timmis, G. M. *Lancet I* (1953) 207.
3. Galton, D. A. G. *Lancet I* (1953) 208.
4. Galton, D. A. G., Till, M. and Wiltshaw, E. *Ann. NY Acad. Sci.* 68 (1958) 967.
5. *The Merck Index*, 12th ed., 1996, No. 7635.
6. Horrom, B. W. and Carbon, J. A. (Abbott Laboratories) U.S. 3,293,253 (1966); *Chem. Abstr.* 66 (1967) 55516.
7. Hudson, R. F., Timmis, G. M. and Marshall, R. D. *Biochem. Pharmacol.* 1 (1958) 48.
8. Senning, A., Buchholt, H. C. and Bierling, R. *Arzneim.-Forsch.* 26 (1976) 1800.
9. Forcier, G. A. and Olver, J. W. *Anal. Chem.* 37 (1965) 1447.
10. Lange, U. and Senning, A. *Chem. Ber.* 124 (1991) 1879; correction *Chem. Ber.* 124 (1991) 2378.
11. Shea, K. J. and Burke, L. D. *J. Org. Chem.* 53 (1988) 318.
12. Senning, A. *Synthesis* (1973) 211.
13. Senning, A., Buchholt, H. C., Bierling, R., Steinhoff, D. and Troßmann, G. (Farbenfabriken Bayer A.-G.) *Ger. Offen.* 2,046,089 (1972); *Chem. Abstr.* 77 (1972) 4899.
14. Senning, A., Buchholt, H. C., Bierling, R., Steinhoff, D. and Troßmann, G. (Farbenfabriken Bayer A.-G.) *Ger. Offen.* 2,046,087 (1972); *Chem. Abstr.* 77 (1972) 19679.
15. Durst, T. and Tin, K.-C. *Can. J. Chem.* 48 (1970) 845.

Received February 17, 1997.